Treatment of <i>ALK</i>-rearranged non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) is challenged by the almost inevitable emergence of therapeutic resistance. Here, ALK is linked to non-small cell lung carcinoma.